UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 16.

Satheesha, S; Manzella, G; Bovay, A; Casanova, E A; Bode, P K; Belle, R; Feuchtgruber, S; Jaaks, P; Dogan, N; Koscielniak, E; Schäfer, B W (2016). Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma. Oncogene, 35(16):2020-2030.

Walter, D; Satheesha, S; Albrecht, P; Bornhauser, B C; D'Alessandro, V; Oesch, S M; Rehrauer, H; Leuschner, I; Koscielniak, E; Gengler, C; Moch, H; Bernasconi, M; Niggli, F K; Schäfer, B W (2011). CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS ONE, 6(5):e19506.

Burger, A; Koesters, R; Schäfer, B W; Niggli, F K (2011). Generation of a novel rtTA transgenic mouse to induce time-controlled, tissue-specific alterations in Pax2-expressing cells. Genesis: The Journal of Genetics and Development, 49(10):797-802.

Schrappe, M; Valsecchi, M G; Bartram, C R; Schrauder, A; Panzer-Grümayer, R; Möricke, A; Parasole, R; Zimmermann, M; Dworzak, M; Buldini, B; Reiter, A; Basso, G; Klingebiel, T; Messina, C; Ratei, R; Cazzaniga, G; Koehler, R; Locatelli, F; Schäfer, B W; Aricò, M; Welte, K; van Dongen, J J M; Gadner, H; Biondi, A; Conter, V (2011). Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 118(8):2077-2084.

Hajdin, K; D'Alessandro, V; Niggli, F K; Schäfer, B W; Bernasconi, M (2010). Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model. PLoS ONE, 5(5):e10445.

Bonapace, L; Bornhauser, B C; Schmitz, M; Cario, G; Ziegler, Urs; Niggli, F K; Schäfer, B W; Schrappe, M; Stanulla, M; Bourquin, J P (2010). Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. Journal of Clinical Investigation, 120(4):1310-1323.

Schäfer, B W; Niggli, F (2010). Multidisciplinary management of childhood sarcoma: time to expand. Expert Review of Anticancer Therapy, 10(8):1163-1166.

Wachtel, M; Schäfer, B W (2010). Targets for cancer therapy in childhood sarcomas. Cancer Treatment Reviews, 36(4):318-327.

Hecker, R M; Amstutz, R A; Wachtel, M; Walter, D; Niggli, F K; Schäfer, B W (2010). p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment. Oncogene, 29(27):3942-3952.

Oesch, S; Walter, D; Wachtel, M; Prêtre, Kathya; Salazar, M; Guzmán, M; Velasco, G; Schäfer, B W (2009). Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Molecular Cancer Therapeutics, 8(7):1838-1845.

Witt, H; Hajdin, K; Iljin, K; Greiner, O; Niggli, F K; Schäfer, B W; Bernasconi, M (2009). Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1. International Journal of Cancer, 124(9):2026-2032.

Grass, B; Wachtel, M; Behnke, S; Leuschner, I; Niggli, F K; Schäfer, B W (2009). Immunohistochemical detection of EGFR, fibrillin-2, P-cadherin and AP2beta as biomarkers for rhabdomyosarcoma diagnostics. Histopathology, 54(7):873-879.

Meyer, C; Kowarz, E; Hofmann, J; Renneville, A; Zuna, J; Trka, J; Ben Abdelali, R; Macintyre, E; De Braekeleer, E; De Braekeleer, M; Delabesse, E; de Oliveira, M P; Cavé, H; Clappier, E; van Dongen, J J M; Balgobind, B V; van den Heuvel-Eibrink, M M; Beverloo, H B; Panzer-Grümayer, R; Teigler-Schlegel, A; Harbott, J; Kjeldsen, E; Schnittger, S; Koehl, U; Gruhn, B; Heidenreich, O; Chan, L C; Yip, S F; Krzywinski, M; Eckert, C; Möricke, A; Schrappe, M; Alonso, C N; Schäfer, B W; Krauter, J; Lee, D A; Zur Stadt, U; Te Kronnie, G; Sutton, R; Izraeli, S; Trakhtenbrot, L; Lo Nigro, L; Tsaur, G; Fechina, L; Szczepanski, T; Strehl, S; Ilencikova, D; Molkentin, M; Burmeister, T; Dingermann, T; Klingebiel, T; Marschalek, R (2009). New insights to the MLL recombinome of acute leukemias. Leukemia, 23(8):1490-1499.

Amstutz, R; Wachtel, M; Troxler, H; Kleinert, P; Ebauer, M; Haneke, T; Oehler-Jänne, C; Fabbro, D; Niggli, F K; Schäfer, B W (2008). Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Research, 68(10):3767-3776.

Flohr, T; Schrauder, A; Cazzaniga, G; Panzer-Grümayer, R; van der Velden, V; Fischer, S; Stanulla, M; Basso, G; Niggli, F K; Schäfer, B W; Sutton, R; Koehler, R; Zimmermann, M; Valsecchi, M G; Gadner, H; Masera, G; Schrappe, M; van Dongen, J J M; Biondi, A; Bartram, C R (2008). Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia, 22(4):771-782.

Mueller, A; Schäfer, B W; Ferrari, S; Weibel, M; Makek, M; Höchli, M; Heizmann, C W (2005). The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. Journal of Biological Chemistry, 280(32):29186-29193.

This list was generated on Fri Jul 21 05:49:40 2017 CEST.